Centrillion Technologies develops high-density DNA chips and molecular assays for genomic analysis, including applications in pathogen detection, whole genome viral sequencing, human genotyping, and spatial transcriptomics. The company leverages advanced photolithography and novel chip design to enable rapid, accurate genomic research and personalized medicine.
Centrillion Technologies has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2009
Employees
51–100
Total Funding
$103M
1 rounds
Total raised $103M across 1 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Aggregate seed-Series C
Date
Amount
$103M
Valuation
—
Lead Investors
Wei Zhou
Founder and CEO
Glenn McGall
Senior Vice President, Technology
Anna Huang
Senior Director of Operations
Competitor list is illustrative and may be incomplete, stale, or erroneous.
10x Genomics
Develops spatial transcriptomics platforms including Visium and Xenium; acquired Centrillion's spatial biology IP in 2023
NanoString Technologies
Offers spatial genomics and transcriptomics solutions through GeoMx and CosMx platforms
Bio-Rad Laboratories
Leading provider of spatial genomics and transcriptomics tools
Illumina
Provides sequencing platforms and software for spatial genomics analysis
Vizgen
Develops MERFISH technology for spatial transcriptomics
Akoya Biosciences
Offers spatial biology and multiplex imaging solutions
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.